dc.contributor.author | LaCourse, SM | |
dc.contributor.author | Cranmer, LM | |
dc.contributor.author | Njuguna, IN | |
dc.contributor.author | Gatimu, J | |
dc.contributor.author | Stern, J | |
dc.contributor.author | Walson, JL | |
dc.contributor.author | Wamalwa, D | |
dc.contributor.author | John-Stewart, G | |
dc.contributor.author | Pavlinac, P | |
dc.date.accessioned | 2018-01-16T05:50:25Z | |
dc.date.available | 2018-01-16T05:50:25Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | 10.1093/cid/ciy011. | en_US |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/29324985 | |
dc.identifier.uri | https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy011/4792803 | |
dc.identifier.uri | http://hdl.handle.net/11295/102355 | |
dc.description.abstract | Despite diagnostic performance limitations, urine lipoarabinomannan (LAM) predicts death in HIV-infected adults with TB. Pediatric data are limited. Among 137 hospitalized HIV-infected children, mortality was 4.9-fold higher among LAM-positives (127 vs. 31/100 py, aHR 4.92 [95%CI 1.79-13.49]; p=0.002). LAM identifies HIV-infected children at risk for death potentially missed by respiratory sampling. | en_US |
dc.language.iso | en | en_US |
dc.publisher | University of Nairobi | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | HIV; children; lipoarabinomannan; mortality; tuberculosis; urine | en_US |
dc.title | Urine TB lipoarabinomannan (LAM) predicts mortality in hospitalized HIV-infected children. | en_US |
dc.type | Article | en_US |